Brief: Casi Pharmaceuticals And Cleave Therapeutics Announce Clinical Trial Application Approval For CB-5339
06/01/2023 12:13
Jan 6 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE
CLINICAL
TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE
MYELOMA IN CHINA
* CASI PHARMACEUTICALS INC: EXPECTED ENROLLMENT TO BEGIN IN
2023
Source text for Eikon: ID:nPn6Yzf4ha
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary